Next Article in Journal
Natural Polymeric Nanobiocomposites for Anti-Cancer Drug Delivery Therapeutics: A Recent Update
Next Article in Special Issue
Cu(ATSM) Increases P-Glycoprotein Expression and Function at the Blood-Brain Barrier in C57BL6/J Mice
Previous Article in Journal
Biopolymer Micro/Nanogel Particles as Smart Drug Delivery and Theranostic Systems
Previous Article in Special Issue
Differential Expression of ABC Transporter Genes in Brain Vessels vs. Peripheral Tissues and Vessels from Human, Mouse and Rat
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Pharmaceutics
Volume 15
Issue 8
10.3390/pharmaceutics15082062
pharmaceutics-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Distribution of Monocarboxylate Transporters in Brain and Choroid Plexus Epithelium

by
Masaki Ueno
1,*,
Yoichi Chiba
1,
Ryuta Murakami
1,
Yumi Miyai
1,
Koichi Matsumoto
1,
Keiji Wakamatsu
1,
Genta Takebayashi
2,
Naoya Uemura
2 and
Ken Yanase
2
1
Department of Pathology and Host Defense, Faculty of Medicine, Kagawa University, Takamatsu 761-0793, Kagawa, Japan
2
Department of Anesthesiology, Faculty of Medicine, Kagawa University, Takamatsu 761-0793, Kagawa, Japan
*
Author to whom correspondence should be addressed.
Pharmaceutics 2023, 15(8), 2062; https://0-doi-org.brum.beds.ac.uk/10.3390/pharmaceutics15082062
Submission received: 31 May 2023 / Revised: 26 July 2023 / Accepted: 28 July 2023 / Published: 31 July 2023
(This article belongs to the Special Issue Roles of Transporters and Receptors in Drug Delivery to the Brain in Health and Disease)
Browse Figures
Review Reports Versions Notes

Abstract

:
The choroid plexus (CP) plays central roles in regulating the microenvironment of the central nervous system by secreting the majority of cerebrospinal fluid (CSF) and controlling its composition. A monolayer of epithelial cells of CP plays a significant role in forming the blood–CSF barrier to restrict the movement of substances between the blood and ventricles. CP epithelial cells are equipped with transporters for glucose and lactate that are used as energy sources. There are many review papers on glucose transporters in CP epithelial cells. On the other hand, distribution of monocarboxylate transporters (MCTs) in CP epithelial cells has received less attention compared with glucose transporters. Some MCTs are known to transport lactate, pyruvate, and ketone bodies, whereas others transport thyroid hormones. Since CP epithelial cells have significant carrier functions as well as the barrier function, a decline in the expression and function of these transporters leads to a poor supply of thyroid hormones as well as lactate and can contribute to the process of age-associated brain impairment and pathophysiology of neurodegenerative diseases. In this review paper, recent findings regarding the distribution and significance of MCTs in the brain, especially in CP epithelial cells, are summarized.

1. Introduction

1.1. Barrier Function in Choroid Plexus

The brain restricts the entrance of ions and solutes circulating in the blood by two cellular barriers: the blood–brain barrier (BBB) and blood–cerebrospinal fluid (CSF) barrier (BCSFB) [1,2,3,4]. The BBB is composed of endothelial cells interconnected by tight junctions, two basement membranes, pericytes, and end-feet of astrocytes [1,5,6,7,8,9]. BBB endothelial cells have few vesicles and no fenestrations in the cytoplasm, whereas the endothelial cells are equipped with various transporters to supply energy from the blood to brain cells, such as (a) carbohydrate transporters, (b) monocarboxylate transporters (MCTs), (c) amino acid transporters, (d) fatty acid transporters, (e) nucleotide transporters, (f) hormone transporters, (g) organic anion and cation transporters, and (h) other transporters, including those for amines and choline [2,3,4,9]. However, barrier and carrier functions of BBB are affected by various invasions in disease states [7]. Accordingly, BBB dysfunction leads to various brain dysfunctions, such as cognitive dysfunction. On the other hand, endothelial cells of capillaries in the choroid plexus (CP) are originally fenestrated, allowing the passage of intravascular low-molecular-weight substances as well as ions in CP with a vascularized stroma [8,10,11,12]. Every CP has a vascularized stroma and is covered by a monolayer of epithelial cells interconnected by tight and adherens junctions. The tight junction contains occludins and claudins, which bind to cytosolic zonula occludens protein-1 (ZO-1) [10,11]. On the other hand, the adherens junction is distributed beneath the tight junction and contains cadherins, which bind to catenins distributed along the lateral surface of the cytoplasm of CP epithelial cells (CPEs) [10,11]. Accordingly, neighboring CPEs serve as a barrier between the blood and CSF, referred to as BCSFB, and restrict the entry of intravascular substances into ventricles [8,9].

1.2. Characterization of Choroid Plexus Epithelial Cells

CSF is produced through several kinds of ion and water transporters located in CPEs [1,10,11,13]. CPEs are characterized by the presence of various epithelial cytokeratins, β-catenin, vimentin, S-100 protein, podoplanin, and transthyretin/prealbumin [10,11,13,14,15,16]. Intermediate filaments in CPEs have been identified as keratins 8, 18, and possibly 19 [10,17,18]. Miettinen et al. [18] revealed immunoreactivity for cytokeratin (CK) 19 in CP tissues of human brains by immunoblotting, whereas Kasper et al. [17] found no immunoreactivity for CK 19 in CPEs of human brains by immunohistochemistry. We could not confirm immunoreactivity for CK19 (Progen, Biotechnik GmbH, Heidelberg, Germany, 61010) in human CPEs, although immunoreactivities for CK8 and CK18 were confirmed to be present in CPEs (Figure 1a–c). Justice et al. reported that strong immunoreactivity for α-1-antichymotrypsin was present in apical granular organelles in the cytoplasm of adult CPEs [19]. We confirmed, as shown here by immunostaining, that β-catenin, vimentin, S-100, podoplanin, transthyretin, and α-1-antichymotrypsin are expressed in the cytoplasmic membrane or cytoplasm of human CPEs (Figure 1d–i). In addition, representative transporters related to CSF production, such as Na+, -K+, -ATPase, aquaporin 1 (AQP1), and anion exchange protein 2 (AE2), are present in apical or basolateral cytoplasmic membranes of CPEs (Figure 1j–l) [10,11,12,13].
BBB and BCSFB not only have barrier functions but also carrier functions for intracerebral transport of essential nutrients such as glucose, lactate, and amino acids [1,2,3,4,9]. In addition, they play important roles in the removal of metabolic wastes and neurotoxic substances such as amyloid β (Aβ) [1,2,8,20,21]. It is well-known that one of the significant functions of CP is to produce and secrete CSF [11,20]. Accordingly, CPEs are equipped with transporters for ions and organic solutes that are different from those in BBB endothelial cells [1,2,8,21,22]. We previously reviewed the distribution of transporters for glucose, fructose, and urate [23]. Accordingly, in this review paper, we focused on recent findings on the distribution of MCTs in the brain, especially in CPEs. In the brain, MCTs 1, 2, 3, and 4 transport lactate, pyruvate, and ketone bodies, whereas MCT8 transports thyroid hormones. In this manuscript, previously reported results on the distribution of these MCTs in CPEs were summarized and confirmed by immunohistochemical staining. Then, their physiological function and the pathophysiological importance of their expression at BCSFB in neurological diseases were discussed. Table 1 shows a summary of clinicopathological profiles of autopsied human brains that were removed at Kagawa University Hospital, as introduced in our previously published papers [24,25]. Table 2 shows a summary of antibodies used in this manuscript. Before incubation with some antibodies, antigen retrieval was performed by heating sections in 10 mM sodium citrate buffer (pH 6) or 1 mM tris(hydroxymethyl)aminomethane (Tris)-ethylenediaminetetraacetic acid (EDTA) buffer (pH 9) for 20 min. These studies using autopsied human brains were approved by the institutional Ethics Committee of the Faculty of Medicine, Kagawa University, in accordance with the Declaration of Helsinki [24,25]. Then, these brain samples were used to confirm the distribution of substances, including MCTs, in this review manuscript.

2. Monocarboxylate Transporters in the Brain

MCTs catalyze the proton-linked influx or efflux of monocarboxylates such as L-lactate, pyruvate, and ketone bodies in various cells of several organs [26,27]. Consequently, MCTs enable the 1:1 exchange of monocarboxylate and protons across the cellular membrane [26,27]. The direction of transport depends on their intracellular and extracellular concentrations [27]. It is well-known that there are four isoforms, MCTs 1, 2, 3, and 4, in the brain. They belong to the SLC16 family of solute carriers, which has 14 members in total. The family includes MCTs to transport thyroid hormones. MCT8, which is a high-affinity transporter for 3,5,3′-triiodothyronine (T3), MCT10, which is the most homologous to MCT8, and eight orphan members also constitute the family [28]. MCTs 1–4 catalyze proton-coupled lactate transport, whereas MCT8 and MCT10 catalyze the sodium- and proton-independent transport of thyroid hormones [28,29]. In the brain, it is known that MCT1, MCT2, and MCT4 are widely expressed in several kinds of cells [30,31]. MCT1 is mainly expressed on endothelial cells with the barrier function both in humans and rodents [32,33]. MCT2 and MCT4 are mainly expressed in neurons and astrocytes, respectively. On the other hand, MCT3 is expressed in the retinal pigment epithelium and CPEs of mice [34,35]. Protein expression levels in plasma membrane fractions of isolated CP of humans and rats were measured using quantitative targeted absolute proteomics [36]. The study identified low-level expression of MCT1 and MCT3 in rats, low-level expression of MCT1 in humans, and very-low-level expression of MCT4 and MCT5 in humans [36]. It is likely that the expression level of transporters for lactate, pyruvate, and ketone bodies in CPEs affects their CSF concentrations. Their values in CSF have been reported in various diseased brains. Glucose transporters belong to either SLC2A/GLUT or SLC5A/SGLT families and are summarized in some papers [23,37,38]. In this review manuscript, the distributions of MCT1, MCT2, MCT3, MCT4, MCT5, and MCT8, which were previously reported to be present in CPEs, were first reviewed. In addition, detailed localization of MCTs in the brain, especially in cerebral microvessels and CPEs, was confirmed by immunohistochemical staining, as the microvessels and CPEs are important routes to transport intravascular substances from the blood into the brain.

2.1. MCT1 (SLC16A1) Distribution in the Brain and CPEs

MCT1 is well-known to be expressed ubiquitously in the brain. MCT1 expression was reported in endothelial cells, astrocytes [39,40,41], and oligodendrocytes [42]. Lactate is released from astrocytes via MCT4 and may be carried into oligodendrocytes via MCT1 [42]. It was reported that MCT1 was immunohistochemically expressed in microglia in healthy human brains [40] and on the apical side of the cytoplasm of CPEs in autopsied diseased human brains [43]. Immunoreactivity for MCT1 (Abcam, ab90582) is confirmed to be expressed in endothelial cells, reactive astrocytes, and on the apical side of the cytoplasm of CPEs (Figure 2a–c).

2.2. MCT2 (SLC16A7) Distribution in the Brain and CPEs

MCT2 catalyzes the proton-coupled transport of many monocarboxylates, including lactate, pyruvate, and ketone bodies, across the plasma membrane. MCT2 shows the highest affinity for lactate [29] and is also a high-affinity pyruvate transporter. The MCT2 gene is known to be transcribed with high-sensitivity in response to hypoxia, intracellular pH, and lactate [44]. MCT2 is expressed mainly in neurons and also in astrocytes [45]. Pierre et al. [46], using immunohistochemical techniques, reported that MCT1 was strongly expressed in astrocytes of mice, whereas MCT2 was expressed in a small subset of neurons of mice. These findings are consistent with the concept that lactate is released by astrocytes via MCT1 and is taken up into neurons via MCT2. They also reported [46] that CPEs of mice were heavily immunostained for MCT2 as well as MCT1. On MCT2 expression in human brains, immunoreactivity for MCT2 was present in neuronal axons, microglia, and endothelial cells in healthy human brains and additionally in astrocytes in brains of multiple sclerosis patients [41]. Immunoreactivity for MCT2 (Abcam, ab198272) is confirmed to be present in neuronal cytoplasm, endothelial cells, and reactive astrocytes, and on the apical side of the cytoplasm of human CPEs, as shown in Figure 2d–f.

2.3. MCT4 (SLC16A3) Distribution in the Brain and CPEs

MCT4 is a low-affinity high-capacity transporter and is expressed mainly in astrocytes [47]. MCT4 is known to facilitate the excretion of lactate in cells, in which glycolysis is highly active [48]. Immunoreactivity for MCT4 was present in microglia and endothelial cells as well as astrocytes of healthy human brains [41]. Murakami et al. [43] reported that MCT4 immunoreactivity was present in endothelial cells and reactive astrocytes, and on the basolateral side of the cytoplasm of CPEs in diseased human brains. Immunoreactivity for MCT4 (Abcam, ab244385) can be noted in the same location as reported previously (Figure 2g–i).

2.4. MCT3 (SLC16A8) Distribution in CPEs

MCT3 protein and mRNA of mice were detected in the retinal pigment epithelium and CPEs by immunohistochemistry and Western and Northern blot analyses [34]. Immunoreactivity for MCT3 was noted in the basolateral membrane of CPEs of mice. MCT3 expression was also reported to be detected in rat CP but not in human samples by quantitative targeted absolute proteomics [36]. MCT3 immunoreactivity (Abcam, ab60333) is seen in the cytoplasm of CPEs but not in microvessels (Figure 2j,k).

2.5. MCT5 (SLC16A4) Distribution in the Brain

The expression of MCT5 in the brain was reported in a paper by Halestrap et al. [26] and also shown in the isolated human CP by quantitative targeted absolute proteomics [36]. Beckner et al. [49] reported that MCT5 expression is increased in some glioblastoma cells. Immunoreactivity for MCT5 (Abcam, ab191008) is not seen in the diseased human brain, including CPEs (Figure 2l,m).

2.6. MCT8 (SLC16A2) Distribution in the Brain and CPEs

MCT8, also known as SLC16A2, was first cloned in 1994 and called XPCT because it was encoded by the XPCT gene in Xq13.2. [50]. After MCT10 was identified to be originally an aromatic amino acid transporter, MCT8 was established as an active transporter to transport iodothyronines, including the thyroid hormones T3 and T4 [51]. It is now considered that MCT8, MCT10, and organic anion transporting polypeptide 1C1 (OATP1C1) are the best-characterized specific thyroid hormone transporters [28,52]. MCT8 is widely expressed in most tissues, including the liver, kidney, heart, skeletal muscle, brain, pituitary, and thyroid [53]. It plays a major role in thyroid hormone uptake across the BBB [54]. In brains of humans and mice, MCT8 protein was reported to be expressed in the cortex, hippocampus, cerebellum, hypothalamus, tanycytes, cerebral vessels, and CP [55,56,57]. Roberts et al. [55] reported that MCT8 was immunohistochemically expressed in endothelial cells and was also visible on the apical and basal surfaces of human CPEs, whereas immunoreactivity for OATP-14, known as OATP1C1, was present on both apical and basolateral surfaces of CPEs. On the other hand, Roberts et al. stated [55] that MCT8 is expressed on the apical surface of CPEs and OATP14 is present primarily on the basolateral surface of CPEs in human and rodent brains. Wilpert et al. [58] reported that MCT8 protein in human brains was expressed in endothelial cells of BBB, CPEs, and tanycytes, whereas neuronal MCT8 protein was expressed in large quantities in specific brain regions. Alkemade et al. [59] reported that MCT8 was immunohistochemically expressed in neurons and glial cells of the human hypothalamus. In contrast, in mouse brains, MCT8 mRNA was expressed predominantly in neurons and also in CP [60]. Alkemade et al. [61] reported that MCT10 immunocytochemical staining was noted in neurons of hypothalamic nuclei. Mutations of MCT8 cause a severe neurodevelopmental disorder, Allan–Herndon–Dudley syndrome [62], which is an X-linked inherited disorder of brain development with hypomyelinating leukodystrophy. Patients developed several kinds of symptoms, such as hypotonia, primitive reflexes, scoliosis, muscular hypoplasia, and dystonia [62,63]. These indicate that thyroid hormone and MCT8 are essential for nervous system development. Immunoreactivity for MCT8 (Novus, NBP2-57308) is present in endothelial cells and on the apical side of the cytoplasm of CPEs (Figure 2n,o). Confirmatory immunohistochemical images in this manuscript are shown in Figure 1 and Figure 2, whereas previously reported findings on regional distribution and cellular localization of MCTs in many papers are summarized in Table 3.

2.7. Lactate Transport in the Brain through Cerebral Microvessels and CPEs

MCT1 and MCT4 are involved in lactate release by astrocytes and contribute to energy supply by glycolysis in the cells [64,65,66]. MCT4 is a transporter with low affinity and high capacity for lactate and contributes to transport lactate from astrocytes to neurons. In contrast, MCT2 is mainly present in neurons, and lactate is taken up into neurons via MCT2 as an efficient oxidative energy substrate. MCT2 is known to be a transporter with a higher affinity for most monocarboxylates than MCT1 [26]. These MCTs contribute in concert to the astrocyte–neuron lactate shuttling [67,68,69]. Accordingly, the distribution of MCTs in the plasma membrane of neurons and astrocytes suggests a significant role of these transporters in the shuttling of energy metabolites between neurons and astrocytes [67,68,69,70].
It was reported that lactate values in CSF of 7614 individuals increased with aging [71]. Results from a CSF-based study indicated that lactate levels in CSF of Parkinson’s disease (PD) patients increased compared with controls and were correlated with clinical disease progression [72]. On the other hand, lower lactate levels in CSF were reported in patients with dementia, including Alzheimer’s disease (AD) and frontotemporal dementia, compared with non-demented individuals [73]. Accordingly, lactate levels in CSF may be useful for understanding the degree of aging and progression of neurodegenerative diseases. The hydroxy-carboxylic acid 1 receptor (HCA1 receptor), a receptor for lactate, is highly expressed in principal neurons, whereas the receptor is also expressed in astrocytes and endothelial cells [35,74]. In addition, it was recently reported that the HCA1 receptor was expressed in CPEs [43]. Immunoreactivity for the HCA1 receptor (Novus, NLS-2095) is shown to be present in cerebral endothelial cells and on the basolateral membrane of CPEs (Figure 2p,q).

3. Discussion

In this manuscript, we first reviewed the localization and significance of MCTs in cerebral microvessels and CP, and subsequently confirmed the detailed localization of cytoplasmic and membranous molecules reported previously to be expressed in CPEs. As lactate is transported with protons through MCTs in CPEs, representative transporters for water and electrolytes are also described in this review paper. Although MCT5 was not immunohistochemically confirmed to be localized in CPEs, MCT1, MCT2, and MCT4, which are the main transporters for lactate in the brain, were shown to be immunohistochemically expressed in CPEs as well as astrocytes and endothelial cells. MCT2 was also expressed in the cytoplasm of some neurons. MCT3 was shown to be immunohistochemically expressed in the cytoplasm of CPEs. In addition, the HCA1 receptor, which is a receptor for lactate and mediates a decrease in cellular cAMP levels, was immunohistochemically expressed in cerebral microvessels and CPEs. Polarized distributions of MCT1, MCT2, MCT3, MCT4, and HCA1-R and putative directions of lactate through CPEs are indicated by dashed arrows in Figure 3. Considering the movement of lactate between astrocytes and neurons via MCTs, it can be suggested that lactate is transported from CSF into the cytoplasm of CPEs via MCT2 and is released to the CP stroma via MCT4, whereas MCT1 may facilitate the transport of lactate from the cytoplasm of CPEs into CSF (Figure 3). At present, however, the directions cannot be determined. It remains to be clarified whether MCT3 is involved in the transport of lactate in CPEs.
Lactate values in CSF are known to increase with aging [71]. Lactate levels in PD patients increased compared with those of controls [72], whereas lower CSF lactate levels were reported in patients suffering from dementia, including AD, compared with non-demented individuals [73]. It is likely that excess exposure to lactate in brain tissues causes acidic tissue injury. On the other hand, lower CSF lactate levels may suggest the impaired function of lactate transport through MCT1, MCT2, MCT3, and/or MCT4 in CPEs in patients with dementia. The specific mechanism of energy supply to the brain in patients with neurodegenerative diseases has not yet been elucidated.
Thyroid hormones are considered to be involved not only in in neurogenesis and neurodifferentiation, but also in cognitive functions. It is interesting that hippocampal neurons are considered to be affected by thyroid hormone levels [75]. It has been pointed out that hypothyroidism is frequently associated with cognitive impairment and/or depressive-like behavior [76]. At present, however, specific foci responsible for symptoms of brain disorders, such as cognitive impairment, in patients with hypothyroidism, remain to be clarified. In addition, it is unclear why hippocampal neurons are affected in hypothyroidism. A large-scale study [77] showed that patients with hypothyroidism had a higher risk of memory impairment and also had a more than three-fold increase in the dementia risk. Several studies have reported an association between thyroid disorders and AD. However, there remains no consensus regarding the precise role of thyroid dysfunction in AD. A meta-analysis using clinical subject headings and keywords from databases [78] showed no significant association of hypothyroidism and the risk of cognitive dysfunction without adjustment for vascular comorbidities. On the other hand, another meta-analysis using some databases [79] showed that hypothyroidism was significantly more prevalent in patients with AD than in controls. It is likely that these discrepancies in findings on hypothyroidism in patients with dementia are due to the multiple causes of cognitive impairment.
MCT8, an active transporter that transports thyroid hormones [51,52], was reported to be expressed in endothelial cells but also in CPEs [55,58]. Also in this paper, MCT8 immunoreactivity was shown in CPEs as well as endothelial cells. These findings suggest that thyroid hormones can be transported from the blood into the hippocampus through these cells. There are two hypothesized mechanisms for thyroid hormones to move out of CP into CSF: one is the secretion of thyroid hormones bound to CP-derived transthyretin, and the other is the efflux of thyroid hormones via thyroid hormone transporters in CPEs such as MCT8 [80], as shown in Figure 3. Although putative directions of thyroid hormones through CPEs are also indicated by dashed arrows in Figure 3, these cannot be confirmed.

4. Conclusions and Future Direction

This paper reviewed the distribution of MCTs as transporters for lactate and thyroid hormones in the brain, especially in endothelial cells and CPEs. Lactate and thyroid hormones are important for the maintenance of several kinds of brain function. It is likely that their insufficiency or excess exposure to them due to CP damage causes brain dysfunction. Recent developments in brain imaging have increased the capacity to diagnose brain diseases. Functional 1H magnetic resonance spectroscopy (fMRS) is becoming a powerful diagnostic tool for brain diseases [81]. It was reported that lactate evaluated with fMRS has the potential to be a new diagnostic and prognostic marker for AD [81]. As the mitochondrial glycolysis pathway is considered to be disrupted in many brain disorders, the activation of anaerobic glycolysis with increased lactate production must occur in the presence of various brain disorders. Along with the development of brain imaging, the importance of lactate measurement will likely increase.

Author Contributions

M.U., Y.C. and K.M. wrote the manuscript. R.M., Y.M., K.W., G.T., N.U. and K.Y. reviewed the draft. M.U., Y.C., R.M., K.M. and K.W. made photos and figures. Y.C., R.M., Y.M., K.M., K.W., G.T., N.U. and K.Y. prepared samples and performed staining. All authors have read and agreed to the published version of the manuscript.

Funding

This paper was supported by grants from JSPS KAKENHI, 19K07508 (YC), 20K16193 (RM), and 20K16550 (NU) of Japan.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Redzic, Z. Molecular biology of the blood-brain and the blood-cerebrospinal fluid barriers: Similarities and differences. Fluids Barriers CNS 2011, 8, 3. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  2. Sweeney, M.D.; Zhao, Z.; Montagne, A.; Nelson, A.R.; Zlokovic, B.V. Blood-Brain Barrier: From Physiology to Disease and Back. Physiol. Rev. 2019, 99, 21–78. [Google Scholar] [CrossRef] [PubMed]
  3. Uchida, Y.; Goto, R.; Takeuchi, H.; Luczak, M.; Usui, T.; Tachikawa, M.; Terasaki, T. Abundant Expression of OCT2, MATE1, OAT1, OAT3, PEPT2, BCRP, MDR1, and xCT Transporters in Blood-Arachnoid Barrier of Pig and Polarized Localizations at CSF- and Blood-Facing Plasma Membranes. Drug Metab. Dispos. 2020, 48, 135–145. [Google Scholar] [CrossRef] [PubMed]
  4. Huttunen, K.M.; Terasaki, T.; Urtti, A.; Montaser, A.B.; Uchida, Y. Pharmacoproteomics of Brain Barrier Transporters and Substrate Design for the Brain Targeted Drug Delivery. Pharm. Res. 2022, 39, 1363–1392. [Google Scholar] [CrossRef]
  5. Reese, T.S.; Karnovsky, M.J. Fine structural localization of a blood-brain barrier to exogenous peroxidase. J. Cell Biol. 1967, 34, 207–217. [Google Scholar] [CrossRef] [PubMed]
  6. Brightman, M.W.; Reese, T.S. Junctions between intimately apposed cell membranes in the vertebrate brain. J. Cell Biol. 1969, 40, 648–677. [Google Scholar] [CrossRef]
  7. Liebner, S.; Dijkhuizen, R.M.; Reiss, Y.; Plate, K.H.; Agalliu, D.; Constantin, G. Functional morphology of the blood–brain barrier in health and disease. Acta Neuropathol. 2018, 135, 311–336. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  8. Ueno, M.; Chiba, Y.; Murakami, R.; Matsumoto, K.; Fujihara, R.; Uemura, N.; Yanase, K.; Kamada, M. Disturbance of Intracerebral Fluid Clearance and Blood–Brain Barrier in Vascular Cognitive Impairment. Int. J. Mol. Sci. 2019, 20, 2600. [Google Scholar] [CrossRef] [Green Version]
  9. Morris, M.E.; Rodriguez-Cruz, V.; Felmlee, M.A. SLC and ABC Transporters: Expression, Localization, and Species Differences at the Blood-Brain and the Blood-Cerebrospinal Fluid Barriers. AAPS J. 2017, 19, 1317–1331. [Google Scholar] [CrossRef]
  10. Damkier, H.; Praetorius, J. Structure of the mammalian choroid plexus. In Role of the Choroid Plexus in Health and Disease; Praetorius, J., Blazer-Yost, B., Damkier, H., Eds.; Springer: New York, NY, USA, 2020; pp. 1–33. [Google Scholar]
  11. Praetorius, J.; Damkier, H.H. Transport across the choroid plexus epithelium. Am. J. Physiol. Physiol. 2017, 312, C673–C686. [Google Scholar] [CrossRef]
  12. Pardridge, W.M. CSF, blood-brain barrier, and brain drug delivery. Expert Opin. Drug Deliv. 2016, 13, 963–975. [Google Scholar] [CrossRef] [PubMed]
  13. Wakamatsu, K.; Chiba, Y.; Murakami, R.; Miyai, Y.; Matsumoto, K.; Kamada, M.; Nonaka, W.; Uemura, N.; Yanase, K.; Ueno, M. Metabolites and Biomarker Compounds of Neurodegenerative Diseases in Cerebrospinal Fluid. Metabolites 2022, 12, 343. [Google Scholar] [CrossRef] [PubMed]
  14. Lach, B.; Scheithauer, B.W.; Gregor, A.; Wick, M.R. Colloid cyst of the third ventricle. A comparative immunohisto-chemical study of neuraxis cysts and choroid plexus epithelium. J. Neurosurg. 1993, 78, 101–111. [Google Scholar] [CrossRef] [PubMed]
  15. Shibahara, J.; Kashima, T.; Kikuchi, Y.; Kunita, A.; Fukayama, M. Podoplanin is expressed in subsets of tumors of the central nervous system. Virchows Arch. 2006, 448, 493–499. [Google Scholar] [CrossRef] [PubMed]
  16. Kirik, O.V.; Sufieyva, D.A.; Nazarenkova, A.; Korzhevskiy, D.E. Cell contact protein beta-catenin in ependymal and epithelial cells of the choroid plexus of the cerebral lateral ventricles. Morphology 2016, 149, 33–37. [Google Scholar] [PubMed]
  17. Kasper, M.; Karsten, U.; Stosiek, P. Detection of cytokeratin(s) in epithelium of human Plexus choroideus by monoclonal antibodies. Acta Histochem. 1986, 78, 101–103. [Google Scholar] [CrossRef]
  18. Miettinen, M.; Clark, R.; Virtanen, I. Intermediate filament proteins in choroid plexus and ependyma and their tumors. Am. J. Pathol. 1986, 123, 231–240. [Google Scholar]
  19. Justice, D.L.; Rhodes, R.H.; Tökés, Z.A. Immunohistochemical demonstration of proteinase inhibitor alpha-1-antichymotrypsin in normal human central nervous system. J. Cell. Biochem. 1987, 34, 227–238. [Google Scholar] [CrossRef]
  20. Damkier, H.H.; Brown, P.D.; Praetorius, J. Cerebrospinal Fluid Secretion by the Choroid Plexus. Physiol. Rev. 2013, 93, 1847–1892. [Google Scholar] [CrossRef] [Green Version]
  21. Spector, R.; Keep, R.F.; Snodgrass, S.R.; Smith, Q.R.; Johanson, C.E. A balanced view of choroid plexus structure and function: Focus on adult humans. Exp. Neurol. 2015, 267, 78–86. [Google Scholar] [CrossRef] [Green Version]
  22. Johanson, C.E.; Keep, R.F. Blending Established and New Perspectives on Choroid Plexus-CSF Dynamics. In Role of the Choroid Plexus in Health and Disease; Springer: Berlin/Heidelberg, Germany, 2020; pp. 35–81. [Google Scholar] [CrossRef]
  23. Chiba, Y.; Murakami, R.; Matsumoto, K.; Wakamatsu, K.; Nonaka, W.; Uemura, N.; Yanase, K.; Kamada, M.; Ueno, M. Glucose, Fructose, and Urate Transporters in the Choroid Plexus Epithelium. Int. J. Mol. Sci. 2020, 21, 7230. [Google Scholar] [CrossRef] [PubMed]
  24. Matsumoto, K.; Chiba, Y.; Fujihara, R.; Kubo, H.; Sakamoto, H.; Ueno, M. Immunohistochemical analysis of transporters related to clearance of amyloid-β peptides through blood–cerebrospinal fluid barrier in human brain. Histochem. Cell Biol. 2015, 144, 597–611. [Google Scholar] [CrossRef]
  25. Wakamatsu, K.; Chiba, Y.; Murakami, R.; Matsumoto, K.; Miyai, Y.; Kawauchi, M.; Yanase, K.; Uemura, N.; Ueno, M. Immunohistochemical expression of osteopontin and collagens in choroid plexus of human brains. Neuropathology 2022, 42, 117–125. [Google Scholar] [CrossRef] [PubMed]
  26. Halestrap, A.P. The SLC16 gene family—Structure, role and regulation in health and disease. Mol. Asp. Med. 2013, 34, 337–349. [Google Scholar] [CrossRef]
  27. Iwanaga, T.; Kishimoto, A. Cellular distributions of monocarboxylate transporters: A review. Biomed. Res. 2015, 36, 279–301. [Google Scholar] [CrossRef] [Green Version]
  28. Friesema, E.C.H.; Jansen, J.; Jachtenberg, J.-W.; Visser, W.E.; Kester, M.H.A.; Visser, T.J. Effective Cellular Uptake and Efflux of Thyroid Hormone by Human Monocarboxylate Transporter 10. Mol. Endocrinol. 2008, 22, 1357–1369. [Google Scholar] [CrossRef] [Green Version]
  29. Halestrap, A.P. The monocarboxylate transporter family-Structure and functional characterization. IUBMB Life 2012, 64, 1–9. [Google Scholar] [CrossRef] [PubMed]
  30. Pierre, K.; Pellerin, L. Monocarboxylate transporters in the central nervous system: Distribution, regulation and function. J. Neurochem. 2005, 94, 1–14. [Google Scholar] [CrossRef]
  31. Vijay, N.; Morris, M.E. Role of Monocarboxylate Transporters in Drug Delivery to the Brain. Curr. Pharm. Des. 2014, 20, 1487–1498. [Google Scholar] [CrossRef] [Green Version]
  32. Smith, J.P.; Drewes, L.R. Modulation of Monocarboxylic Acid Transporter-1 Kinetic Function by the cAMP Signaling Pathway in Rat Brain Endothelial Cells. J. Biol. Chem. 2006, 281, 2053–2060. [Google Scholar] [CrossRef] [Green Version]
  33. Uhernik, A.L.; Li, L.; LaVoy, N.; Velasquez, M.J.; Smith, J.P. Regulation of Monocarboxylic Acid Transporter-1 by cAMP Dependent Vesicular Trafficking in Brain Microvascular Endothelial Cells. PLoS ONE 2014, 9, e85957. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  34. Philp, N.J.; Yoon, H.; Lombardi, L.; Daniele, L.L.; Sauer, B.; Gallagher, S.M.; Pugh, E.N.; Brauchi, S.; Rauch, M.C.; Alfaro, I.E.; et al. Mouse MCT3 gene is expressed preferentially in retinal pigment and choroid plexus epithelia. Am. J. Physiol. Cell Physiol. 2001, 280, C1319–C1326. [Google Scholar] [CrossRef] [PubMed]
  35. Bergersen, L.H. Lactate transport and signaling in the brain: Potential therapeutic targets and roles in body-brain interaction. J. Cereb. Blood Flow. Metab. 2015, 35, 176–185. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  36. Uchida, Y.; Zhang, Z.; Tachikawa, M.; Terasaki, T. Quantitative targeted absolute proteomics of rat blood-cerebrospinal fluid barrier transporters: Comparison with a human specimen. J. Neurochem. 2015, 134, 1104–1115. [Google Scholar] [CrossRef] [PubMed]
  37. Mueckler, M.; Thorens, B. The SLC2 (GLUT) family of membrane transporters. Mol. Asp. Med. 2013, 34, 121–138. [Google Scholar] [CrossRef] [Green Version]
  38. Wright, E.M.; Loo, D.D.F.; Hirayama, B.A. Biology of Human Sodium Glucose Transporters. Physiol. Rev. 2011, 91, 733–794. [Google Scholar] [CrossRef] [Green Version]
  39. Leino, R.L.; Gerhart, D.Z.; Drewes, L.R. Monocarboxylate transporter (MCT1) abundance in brains of sucking and adult rats: A quantitative electron microscopic immunogold study. Brain Res. 1999, 113, 47–54. [Google Scholar] [CrossRef]
  40. Smith, J.P.; Uhernik, A.L.; Li, L.; Liu, Z.; Drewes, L.R. Regulation of Mct1 by cAMP-dependent internalization in rat brain endothelial cells. Brain Res. 2012, 1480, 1–11. [Google Scholar] [CrossRef] [Green Version]
  41. Nijland, P.G.; Michailidou, I.; Witte, M.E.; Mizee, M.R.; van der Pol, S.M.A.; van her Hof, B.; Reijerkerk, A.; Pellerin, L.; van der Valk, P.; de Vries, H.E.; et al. Cellular distribution of glucose and monocarboxylate transporters in human brain white matter and multiple sclerosis lesions. Glia 2014, 62, 1125–1141. [Google Scholar] [CrossRef]
  42. Rinholm, J.E.; Hamilton, N.B.; Kessaris, N.; Richardson, W.D.; Bergersen, L.H.; Attwell, D. Regulation of Oligodendrocyte Development and Myelination by Glucose and Lactate. J. Neurosci. 2011, 31, 538–548. [Google Scholar] [CrossRef] [Green Version]
  43. Murakami, R.; Chiba, Y.; Nishi, N.; Matsumoto, K.; Wakamatsu, K.; Yanase, K.; Uemura, N.; Nonaka, W.; Ueno, M. Immunoreactivity of receptor and transporters for lactate located in astrocytes and epithelial cells of choroid plexus of human brain. Neurosci. Lett. 2021, 741, 135479. [Google Scholar] [CrossRef]
  44. Caruso, J.P.; Koch, B.J.; Benson, P.D.; Varughese, E.; Monterey, M.D.; Lee, A.E.; Dave, A.M.; Kiousis, S.; Sloan, A.E.; Mathupala, S.P. pH, Lactate, and Hypoxia: Reciprocity in Regulating High-Affinity Monocarboxylate Transporter Expression in Glioblastoma. Neoplasia 2017, 19, 121–134. [Google Scholar] [CrossRef] [PubMed]
  45. Hanu, R.; McKenna, M.; O’Neill, A.; Resneck, W.G.; Bloch, R.J.; Takimoto, M.; Hamada, T.; Puchowicz, M.A.; Xu, K.; Sun, X.; et al. Monocarboxylic acid transporters, MCT1 and MCT2, in cortical astrocytes in vitro and in vivo. Am. J. Physiol. Physiol. 2000, 278, C921–C930. [Google Scholar] [CrossRef]
  46. Pierre, K.; Pellerin, L.; Debernardi, R.; Riederer, B.; Magistretti, P. Cell-specific localization of monocarboxylate transporters, MCT1 and MCT2, in the adult mouse brain revealed by double immunohistochemical labeling and confocal microscopy. Neuroscience 2000, 100, 617–627. [Google Scholar] [CrossRef] [PubMed]
  47. Lundquist, A.J.; Llewellyn, G.N.; Kishi, S.H.; Jakowec, N.A.; Cannon, P.M.; Petzinger, G.M.; Jakowec, M.W. Knockdown of Astrocytic Monocarboxylate Transporter 4 in the Motor Cortex Leads to Loss of Dendritic Spines and a Deficit in Motor Learning. Mol. Neurobiol. 2022, 59, 1002–1017. [Google Scholar] [CrossRef] [PubMed]
  48. Dimmer, K.-S.; Friedrich, B.; Lang, F.; Deitmer, J.W.; Bröer, S. The low-affinity monocarboxylate transporter MCT4 is adapted to the export of lactate in highly glycolytic cells. Biochem. J. 2000, 350, 219–227. [Google Scholar] [CrossRef]
  49. Beckner, M.E.; Pollack, I.F.; Nordberg, M.L.; Hamilton, R.L. Glioblastomas with copy number gains in EGFR and RNF139 show increased expressions of carbonic anhydrase genes transformed by ENO1. BBA Clin. 2016, 5, 1–15. [Google Scholar] [CrossRef] [Green Version]
  50. Lafrenière, R.G.; Carrel, L.; Willard, H.F. A novel transmembrane transporter encoded by the XPCT gene in Xq13.2. Hum. Mol. Genet. 1994, 3, 1133–1139. [Google Scholar] [CrossRef]
  51. Friesema, E.C.H.; Ganguly, S.; Abdalla, A.; Manning Fox, J.E.; Halestrap, A.P.; Visser, T.J. Identification of Monocarboxylate Transporter 8 as a Specific Thyroid Hormone Transporter. J. Biol. Chem. 2003, 278, 40128–40135. [Google Scholar] [CrossRef] [Green Version]
  52. Visser, W.E.; Friesema, E.C.; Jansen, J.; Visser, T.J. Thyroid hormone transport in and out of cells. Trends Endocrinol. Metab. 2008, 19, 50–56. [Google Scholar] [CrossRef]
  53. Visser, W.E.; Friesema, E.C.H.; Visser, T.J. Minireview: Thyroid Hormone Transporters: The Knowns and the Unknowns. Mol. Endocrinol. 2011, 25, 1–14. [Google Scholar] [CrossRef] [Green Version]
  54. Wirth, E.K.; Schweizer, U.; Kohrle, J. Transport of Thyroid Hormone in Brain. Front. Endocrinol. 2014, 5, 98. [Google Scholar] [CrossRef] [Green Version]
  55. Roberts, L.M.; Woodford, K.; Zhou, M.; Black, D.S.; Haggerty, J.E.; Tate, E.H.; Grindstaff, K.K.; Mengesha, W.; Raman, C.; Zerangue, N. Expression of the Thyroid Hormone Transporters Monocarboxylate Transporter-8 (SLC16A2) and Organic Ion Transporter-14 (SLCO1C1) at the Blood-Brain Barrier. Endocrinology 2008, 149, 6251–6261. [Google Scholar] [CrossRef] [PubMed]
  56. Wirth, E.K.; Roth, S.; Blechschmidt, C.; Hölter, S.M.; Becker, L.; Racz, I.; Zimmer, A.; Klopstock, T.; Failus-Durner, V.; Fuchs, H.; et al. Neuronal 3’,3,5-triiodothyronine (T3) uptake and behavioral phenotype of mice deficient in Mct8, the neuronal T3 transporter mutated in Allan-Herndon-Dudley syndrome. J. Neurosci. 2009, 30, 9439–9449. [Google Scholar] [CrossRef] [PubMed]
  57. Braun, D.; Kinne, A.; Bräuer, A.U.; Sapin, R.; Klein, M.O.; Köhrle, J.; Wirth, E.K.; Schweizer, U. Developmental and cell type-specific expression of thyroid hormone transporters in the mouse brain and in primary brain cells. Glia 2011, 59, 463–471. [Google Scholar] [CrossRef]
  58. Wilpert, N.-M.; Krueger, M.; Opitz, R.; Sebinger, D.; Paisdzior, S.; Mages, B.; Schulz, A.; Spranger, J.; Wirth, E.K.; Stachelscheid, H.; et al. Spatiotemporal Changes of Cerebral Monocarboxylate Transporter 8 Expression. Thyroid 2020, 30, 1366–1383. [Google Scholar] [CrossRef] [Green Version]
  59. Alkemade, A.; Friesema, E.C.; Unmehopa, U.A.; Fabriek, B.O.; Kuiper, G.G.; Leonard, J.L.; Wiersinga, W.M.; Swaab, D.F.; Visser, T.J.; Fliers, E. Neuroanatomical Pathways for Thyroid Hormone Feedback in the Human Hypothalamus. J. Clin. Endocrinol. Metab. 2005, 90, 4322–4334. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  60. Heuer, H.; Maier, M.K.; Iden, S.; Mittag, J.; Friesema, E.C.H.; Visser, T.J.; Bauer, K. The Monocarboxylate Transporter 8 Linked to Human Psychomotor Retardation Is Highly Expressed in Thyroid Hormone-Sensitive Neuron Populations. Endocrinology 2005, 146, 1701–1706. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  61. Alkemade, A.; Friesema, E.C.H.; Kalsbeek, A.; Swaab, D.F.; Visser, T.J.; Fliers, E. Expression of thyroid hormone trans-porters in the human hypothalamus. J. Clin. Endocrinol. Metab. 2011, 96, E967–E971. [Google Scholar] [CrossRef] [Green Version]
  62. Schwartz, C.E.; May, M.M.; Carpenter, N.J.; Rogers, R.C.; Martin, J.; Bialer, M.G.; Ward, J.; Sanabria, J.; Marsa, S.; Lewis, J.A.; et al. Allan-Herndon-Dudley syndrome and the mono-carboxylate transporter 8 (MCT8) gene. Am. J. Hum. Genet. 2005, 77, 41–53. [Google Scholar]
  63. Wolff, T.M.; Veil, C.; Dietrich, J.W.; Müller, M.A. Mathematical modeling and simulation of thyroid homeostasis: Implications for the Allan-Herndon-Dudley syndrome. Front. Endocrinol. 2022, 13, 882788. [Google Scholar] [CrossRef] [PubMed]
  64. Bröer, S.; Rahman, B.; Pellegri, G.; Pellerin, L.; Martin, J.-L.; Verleysdonk, S.; Hamprecht, B.; Magistretti, P.J. Comparison of Lactate Transport in Astroglial Cells and Monocarboxylate Transporter 1 (MCT 1) Expressing Xenopus laevis Oocytes. Expression of two different monocarboxylate transporters in astroglial cells and neurons. J. Biol. Chem. 1997, 272, 30096–30102. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  65. Maekawa, E.; Minehira, K.; Kadomatsu, K.; Pellerin, L. Basal and stimulated lactate fluxes in primary cultures of astrocytes are differentially controlled by distinct proteins. J. Neurochem. 2008, 107, 789–798. [Google Scholar] [CrossRef] [PubMed]
  66. Rostafio, K.; Pellerin, L. Oxygen tension controls the expression of the monocarboxylate transporter MCT4 in cultures mouse cortical astrocytes via a hypoxia-inducible factor-1alpha-mediated transcriptional regulation. Glia 2014, 62, 477–490. [Google Scholar] [CrossRef] [Green Version]
  67. Pellerin, L.; Pellegri, G.; Bittar, P.G.; Charnay, Y.; Bouras, C.; Martin, J.-L.; Stella, N.; Magistretti, P.J. Evidence Supporting the Existence of an Activity-Dependent Astrocyte-Neuron Lactate Shuttle. Dev. Neurosci. 1998, 20, 291–299. [Google Scholar] [CrossRef]
  68. Pellerin, L. Brain energetics (thought needs fond). Curr. Opin. Clin. Nutr. Metab. Care 2008, 11, 701–705. [Google Scholar] [CrossRef]
  69. Pérez-Escuredo, J.; Van Hée, V.F.; Sboarina, M.; Falces, J.; Payen, V.L.; Pellerin, L.; Sonveaux, P. Monocarboxylate transporters in the brain and in cancer. Biochim. Biophys. Acta (BBA)—Mol. Cell Res. 2016, 1863, 2481–2497. [Google Scholar] [CrossRef] [Green Version]
  70. Bittar, P.G.; Charnay, Y.; Pellerin, L.; Bouras, C.; Magistretti, P.J. Selective Distribution of Lactate Dehydrogenase Isoenzymes in Neurons and Astrocytes of Human Brain. J. Cereb. Blood Flow Metab. 1996, 16, 1079–1089. [Google Scholar] [CrossRef] [Green Version]
  71. Leen, W.G.; Willemsen, M.A.; Wevers, R.A.; Verbeek, M.M. Cerebrospinal Fluid Glucose and Lactate: Age-Specific Reference Values and Implications for Clinical Practice. PLoS ONE 2012, 7, e42745. [Google Scholar] [CrossRef] [Green Version]
  72. Liguori, C.; Stefani, A.; Fernandes, M.; Cerroni, R.; Mercuri, N.B.; Pierantozzi, M. Biomarkers of Cerebral Glucose Metabolism and Neurodegeneration in Parkinson’s Disease: A Cerebrospinal Fluid-Based Study. J. Park. Dis. 2022, 12, 537–544. [Google Scholar] [CrossRef]
  73. Bonomi, C.G.; De Lucia, V.; Mascolo, A.P.; Assogna, M.; Motta, C.; Scaricamazza, E.; Sallustio, F.; Mercuri, N.B.; Koch, G.; Martorana, A. Brain energy metabolism and neurodegeneration: Hints from CSF lactate levels in dementias. Neurobiol. Aging 2021, 105, 333–339. [Google Scholar] [CrossRef] [PubMed]
  74. Lauritzen, K.H.; Morland, C.; Puchades, M.; Holm-Hansen, S.; Hagelin, E.M.; Lauritzen, F.; Attramadal, H.; Storm-Mathisen, J.; Gjedde, A.; Bergersen, L.H. Lactate Receptor Sites Link Neurotransmission, Neurovascular Coupling, and Brain Energy Metabolism. Cereb. Cortex 2014, 24, 2784–2795. [Google Scholar] [CrossRef] [PubMed]
  75. Madeira, M.D.; Sousa, N.; Lima-Andrade, M.T.; Calheiros, F.; Cadete-Leite, A.; Paula-Barbosa, M.M. Selective vulnerability of the hippocampal pyramidal neurons to hypothyroidism in male and female rats. J. Comp. Neurol. 1992, 322, 501–518. [Google Scholar] [CrossRef] [PubMed]
  76. Bakalov, D.; Iliev, P.; Sabit, Z.; Tafradjiiska-Hadjiolova, R.; Bocheva, G. Attenuation of Hypothyroidism-Induced Cognitive Impairment by Modulating Serotonin Mediation. Vet. Sci. 2023, 10, 122. [Google Scholar] [CrossRef]
  77. Stern, M.; Finch, A.; Haskard-Zolnierek, K.B.; Howard, K.; Deason, R.G. Cognitive decline in mid-life: Changes in memory and cognition related to hypothyroidism. J. Health Psychol. 2022, 28, 388–401. [Google Scholar] [CrossRef]
  78. Ye, Y.; Wang, Y.; Li, S.; Guo, J.; Ding, L.; Liu, M. Association of Hypothyroidism and the Risk of Cognitive Dysfunction: A Meta-Analysis. J. Clin. Med. 2022, 11, 6726. [Google Scholar] [CrossRef]
  79. Salehipour, A.; Dolatshahi, M.; Haghshomar, M.; Amin, J. The Role of Thyroid Dysfunction in Alzheimer’s Disease: A Systematic Review and Meta-Analysis. J. Prev. Alzheimer’s Dis. 2023, 10, 276–286. [Google Scholar] [CrossRef]
  80. Richardson, S.J.; Wijayagunaratne, R.C.; D’Souza, D.G.; Darras, V.M.; Van Herck, S.L.J. Transport of thyroid hormones via the choroid plexus into the brain: The roles of transthyretin and thyroid hormone transmembrane transporters. Front. Neurosci. 2015, 9, 66. [Google Scholar] [CrossRef] [Green Version]
  81. Shirbandi, K.B.; Rikhtegar, R.; Khalafi, M.; Attari, M.M.A.; Rahmani, F.; Javanmardi, P.B.; Iraji, S.M.; Aghdam, Z.B.; Rashnoudi, A.M.R. Functional Magnetic Resonance Spectroscopy of Lactate in Alzheimer Disease: A Comprehensive Review of Alzheimer Disease Pathology and the Role of Lactate. Top. Magn. Reson. Imaging 2023, 32, 15–26. [Google Scholar] [CrossRef]
Pharmaceutics 15 02062 g001 550
Figure 1. Distribution of immunoreactivities for CK8 (a), CK18 (b), CK19 (c), β-catenin (d), vimentin (e), podoplanin (f), S-100 (g), transthyretin/prealbumin (h), α1-antichymotrypsin (AACT) (i), Na+, -K+, -ATPase (j), AQP-1 (k), and AE2 (l), in epithelial cells of CP located in lateral ventricles of autopsied human brains. Arrows indicate immunoreactivity for these substances. Immunohistochemical findings from cases 2 (i), 3 (d,g), 6 (a,k), 7 (f,h), and 8 (b,c,e,j,l) are shown. Scale bars indicate 20 μm.
Figure 1. Distribution of immunoreactivities for CK8 (a), CK18 (b), CK19 (c), β-catenin (d), vimentin (e), podoplanin (f), S-100 (g), transthyretin/prealbumin (h), α1-antichymotrypsin (AACT) (i), Na+, -K+, -ATPase (j), AQP-1 (k), and AE2 (l), in epithelial cells of CP located in lateral ventricles of autopsied human brains. Arrows indicate immunoreactivity for these substances. Immunohistochemical findings from cases 2 (i), 3 (d,g), 6 (a,k), 7 (f,h), and 8 (b,c,e,j,l) are shown. Scale bars indicate 20 μm.
Pharmaceutics 15 02062 g001
Pharmaceutics 15 02062 g002 550
Figure 2. Distribution of immunoreactivities for MCT1 (a–c), MCT2 (d–f), MCT4 (g–i), MCT3 (j,k), MCT5 (l,m), MCT8 (n,o), and HCA1-R (p,q), in autopsied human brains. Immunohistochemical findings from cases 1 (g), 3 (a,h,j,k,m,p), 4, (c,f,i), 5 (b,d,l), 6 (e,q), and 8 (n,o) are shown. Immunohistochemical images in microvessels indicated by thin arrows in hippocampal samples are shown in (a,d,f,g,n,p), whereas images in epithelial cells of CP located in lateral ventricles indicated by thick arrows are shown in (b,e,h,k,o,q). Immunohistochemical images in reactive astrocytes in hippocampal samples indicated by short arrows are shown in (c,f,i), whereas MCT2 immunostaining in neurons in hippocampal samples indicated by double arrows is shown in (d). No MCT3 immunostaining in microvessels is shown in (j), whereas no MCT5 immunostaining in microvessels and CPEs is shown in (l,m). Scale bars indicate 20 μm.
Figure 2. Distribution of immunoreactivities for MCT1 (a–c), MCT2 (d–f), MCT4 (g–i), MCT3 (j,k), MCT5 (l,m), MCT8 (n,o), and HCA1-R (p,q), in autopsied human brains. Immunohistochemical findings from cases 1 (g), 3 (a,h,j,k,m,p), 4, (c,f,i), 5 (b,d,l), 6 (e,q), and 8 (n,o) are shown. Immunohistochemical images in microvessels indicated by thin arrows in hippocampal samples are shown in (a,d,f,g,n,p), whereas images in epithelial cells of CP located in lateral ventricles indicated by thick arrows are shown in (b,e,h,k,o,q). Immunohistochemical images in reactive astrocytes in hippocampal samples indicated by short arrows are shown in (c,f,i), whereas MCT2 immunostaining in neurons in hippocampal samples indicated by double arrows is shown in (d). No MCT3 immunostaining in microvessels is shown in (j), whereas no MCT5 immunostaining in microvessels and CPEs is shown in (l,m). Scale bars indicate 20 μm.
Pharmaceutics 15 02062 g002
Pharmaceutics 15 02062 g003 550
Figure 3. Polarized distribution of a receptor for lactate and transporters for lactate and thyroid hormones in CPEs. HCA1-R is expressed in the basolateral membrane of the cytoplasm of CPEs and induces decreased cyclic AMP production in the CPE cytoplasm. MCT1 and MCT2 are present on the apical (CSF-facing) side of CPEs, whereas MCT4 is present on the basal (CP stroma-facing) side of CPEs. MCT3 expression on the basolateral side of CPEs has been reported only in mice [34] but has not been confirmed in human brains, including CPEs [36]. Accordingly, MCT3 is written in italics and surrounded by dotted square lines. Putative directions of lactate through CPEs are indicated by dashed arrows. MCT8 and OATP1C1, which are known to be transporters for thyroid hormones, are considered to be distributed on the apical and basolateral sides of CPEs [55]. Thyroid hormones are considered to move between CSF and the CPE cytoplasm via these transporters. According to the paper reported by Roberts et al. [55], MCT8 is distributed on the apical surface of CPEs, whereas OATP1C1 is present primarily on the basolateral side of CPEs. Putative directions of thyroid hormones through CPEs are indicated by dashed arrows. However, the directions cannot be confirmed. As transthyretin (TTR) is synthesized in CPEs, T4 bound to TTR (TTR-T4) is considered to move from the cytoplasm of CPEs into ventricles.
Figure 3. Polarized distribution of a receptor for lactate and transporters for lactate and thyroid hormones in CPEs. HCA1-R is expressed in the basolateral membrane of the cytoplasm of CPEs and induces decreased cyclic AMP production in the CPE cytoplasm. MCT1 and MCT2 are present on the apical (CSF-facing) side of CPEs, whereas MCT4 is present on the basal (CP stroma-facing) side of CPEs. MCT3 expression on the basolateral side of CPEs has been reported only in mice [34] but has not been confirmed in human brains, including CPEs [36]. Accordingly, MCT3 is written in italics and surrounded by dotted square lines. Putative directions of lactate through CPEs are indicated by dashed arrows. MCT8 and OATP1C1, which are known to be transporters for thyroid hormones, are considered to be distributed on the apical and basolateral sides of CPEs [55]. Thyroid hormones are considered to move between CSF and the CPE cytoplasm via these transporters. According to the paper reported by Roberts et al. [55], MCT8 is distributed on the apical surface of CPEs, whereas OATP1C1 is present primarily on the basolateral side of CPEs. Putative directions of thyroid hormones through CPEs are indicated by dashed arrows. However, the directions cannot be confirmed. As transthyretin (TTR) is synthesized in CPEs, T4 bound to TTR (TTR-T4) is considered to move from the cytoplasm of CPEs into ventricles.
Pharmaceutics 15 02062 g003
Table
Table 1. Summary of clinicopathological profiles.
Table 1. Summary of clinicopathological profiles.
(No.)Age/SexMain Diagnosis
160/MDissecting aneurysm
264/MMultiple system atrophy, Pneumonia
370/MMyocardial infarction
471/MCerebellar tuberculosis
572/FPneumonia
674/MLung cancer
775/MGastric cancer
884/MMyocardial infarction, Cerebral infarction
Table
Table 2. Summary of antibodies used.
Table 2. Summary of antibodies used.
AntibodyCat. No. (Clone Name)Host Species and Usage
CK8Progen, 61038mouse, 1:50 (¶2)
CK18ProteinTech, 66187-1-lgmouse, 1:600 (¶2)
CK19Progen, 61010mouse, 1:10 (¶1)
β-cateninSantaCruz, sc-7199rabbit, 1:50 (-)
vimentinDAKO, M0725 (V9)mouse, 1:50 (¶1)
D2/40(podoplanin)DAKO, M3619mouse, 1:50 (¶1)
s-100Nichirei, 422091rabbit, diluted (-)
transthyretinProteinTech, 11891-1-APrabbit, 1:100 (-)
AACTProteinTech, 66078-1-lgmouse, 1:500 (¶2)
Na+,-K+,-ATPaseSantaCruz, sc-48345rabbit, 1:100 (¶1)
Aquaporin-1ProteinTech, 20333-1-APrabbit, 1:250 (¶2)
AE2sc-376632 (D-3)mouse, 1:100 (¶1)
MCT1Abcam, ab90582mouse, 1:100 (¶1)
MCT2Abcam, ab198272rabbit, 1:100 (-)
MCT3Abcam, ab60333rabbit, 1:200 (-)
MCT4Abcam, ab244385rabbit, 1:50 (¶1)
MCT5Abcam, ab191008rabbit, 1:500 (¶1)
MCT8Novus, NBP2-57308rabbit, 1:200 (¶1)
HCA1-RNovus, NLS-2095rabbit, 1:200 (¶1)
(¶1, ¶2): Antigen retrieval with citrate buffer (pH 6) or Tris-EDTA buffer (pH 9) is needed prior to the application of the primary antibody. AACT: α1-antichymotrypsin.
Table
Table 3. Regional distribution and cellular localization of MCTs in the brain.
Table 3. Regional distribution and cellular localization of MCTs in the brain.
Isoform (Gene)Predominat SubstratesRegional DistributionCellular LocalizationReferences
MCT1 (SLC16A1)Lactate, pyruvate,WidespreadEndothelial cells, astrocytes[24,27,30,33,39,40,41,42,43,44,45]
ketone bodiesCortex, hippocampus,ependymocytes, microglia,
cerebellum,oligodensrocyte,
choroid plexuschoroid plexus epithelium,
some neurons (Rt) #1
MCT2 (SLC16A7)Pyruvate, lactate,WidespreadNeurons/axon, microglia,[26,27,41,45]
ketone bodiesCortex, hippocampus,endothelial cells,
(high affinity)cerebellum,choroid plexus epithelium
choroid plexusastrocytes (Rt, MS) #2
MCT3 (SLC16A8)LactateLocalizedRetinal pigment epithelium (Ms) #3,[26,34,35]
choroid plexus epithelium (Ms) #3
MCT4 (SLC16A3)Lactate, pyruvate,WidespreadAstrocytes, microglia[26,27,41,43,46]
ketone bodiesCortex, hippocampus,endothelial cells,
(low affinity)cerebellum,choroid plexus epithelium
(high capacity)choroid plexus
MCT5 (SLC16A4)OrphanLocalizedIsolated choroid plexus[26,36]
MCT8 (SLC16A2)Thyroid hormoneWidespreadNeurons, astrocytes,[26,53,54,55,56,57]
(high affinity)Cortex, hippocampus,endothelial cells
hypothalamus,choroid plexus epithelium
choroid plexus
Italics indicate findings in rodents or humans with neurodegenerative diseases. #1: MCT1 expression is detected in some neurons of rats (Rt) [39]. #2: MCT2 expression is detected in end-feet of astrocytes in rats (Rt) [45] and astrocytes in brains in the presence of multiple sclerosis (MS) [41]. #3: MCT3 expression is detected in retinal pigment and choroid plexus epithelia of mice (Ms) [34].
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Ueno, M.; Chiba, Y.; Murakami, R.; Miyai, Y.; Matsumoto, K.; Wakamatsu, K.; Takebayashi, G.; Uemura, N.; Yanase, K. Distribution of Monocarboxylate Transporters in Brain and Choroid Plexus Epithelium. Pharmaceutics 2023, 15, 2062. https://0-doi-org.brum.beds.ac.uk/10.3390/pharmaceutics15082062

AMA Style

Ueno M, Chiba Y, Murakami R, Miyai Y, Matsumoto K, Wakamatsu K, Takebayashi G, Uemura N, Yanase K. Distribution of Monocarboxylate Transporters in Brain and Choroid Plexus Epithelium. Pharmaceutics. 2023; 15(8):2062. https://0-doi-org.brum.beds.ac.uk/10.3390/pharmaceutics15082062

Chicago/Turabian Style

Ueno, Masaki, Yoichi Chiba, Ryuta Murakami, Yumi Miyai, Koichi Matsumoto, Keiji Wakamatsu, Genta Takebayashi, Naoya Uemura, and Ken Yanase. 2023. "Distribution of Monocarboxylate Transporters in Brain and Choroid Plexus Epithelium" Pharmaceutics 15, no. 8: 2062. https://0-doi-org.brum.beds.ac.uk/10.3390/pharmaceutics15082062

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop